Progress in Sickle Cell Disease: Bending the Biomedical Arc Toward Health Equity - Chard Oncology
Objectives and Disclosures
Participants will be able to:
- Analyze recent scientific advances for sickle cell disease including gene therapy.
- Assess Sickle Cell Disease as a study of the complexities of race and science.
Seattle Children’s Planners disclose they have no relevant financial relationships.
Speaker discloses that she receives grant/research support from and is a consultant for Beam, Bluebird bio, Editas, Novo Nordisk and Novartis. She is also a consultant for Vartex and receives grant/research support from Novartis.
Alexis Thompson, MD, MPH
Chief of Division of Hematology, Children’s Hospital of Philadelphia; Elias Schwartz, MD Endowed Chair in Hematology
CME Credit
Seattle Children’s is accredited by the Washington State Medical Association CME Accreditation Committee to sponsor continuing medical education for physicians.
Seattle Children’s designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the criteria for up to 1 hour of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
Videos are available for only one year after posting.
If you wish to receive Category I CME credit for viewing this Provider Grand Rounds session, please complete the evaluation form. Upon completion of the form you will receive an auto-reply email that will serve as the only confirmation of your CME credit. Please keep the email for your records.
Provider News
The monthly Provider News email provides updates for healthcare professionals about programs and services at Seattle Children’s.
Want to receive Provider News via email? Subscribe now.